Latest news with #IndustryandTrade
Morocco World
4 days ago
- Business
- Morocco World
Morocco Signs Deals for Eight New Sustainable Industrial Projects
Rabat – Several partnership agreements were signed Tuesday in Rabat for eight projects selected under the second edition of the Sustainable Industrial Zones Fund (FONZID II). The projects were chosen through a national call for proposals and represent a total investment of nearly MAD 989 million, including MAD 138 million in funding from the FONZID II. The goal is to increase the supply of high-quality industrial land by creating, expanding, and upgrading industrial zones that meet sustainable, inclusive, and competitive standards. The selected projects include the creation of a new industrial zone in Oued Zem, the creation of an economic activity zone in Ameur, the development of a sustainable industrial park in Taroudant, and upgrading the industrial zone of Ait Melloul. It also includes renovating the Ain Chkef multi-service industrial zone, developing an industrial park in Mohammedia, turning an industrial zone in the Tangier-Tetouan-Al Hoceima region into a green zone, and creating a 'Fertiparc' industrial area in Khouribga. Ryad Mezzour, Minister of Industry and Trade, attended the signing ceremony. The signed agreements support the government's goal of building a new model for sustainable industrial zones, he said, adding that the initiative will boost investment and help improve the economic, social, and environmental performance of businesses in Morocco. 'These projects are important examples of success,' Mezzour added. 'They are part of our efforts to make Morocco a regional leader in sustainable industry.' Akram Allaoui, Director of Industrial Zones at the Ministry, noted that the new agreements aim to achieve three main goals, including modernizing existing industrial zones, developing new ones, and creating zones dedicated to trade. FONZID II provides funding that can cover up to 50% of the total cost, with a maximum of MAD 30 million for new or expanded zones, and up to MAD 20 million for renovation projects. Tags: industrysustainable industry
Business Upturn
5 days ago
- Business
- Business Upturn
New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration
Sydney, Australia: Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister's visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. This press release features multimedia. View the full release here: Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. 'Novotech is a fantastic success story demonstrating the global value of NSW's strengths in life sciences and clinical trials,' said Minister Chanthivong. 'I was thrilled to learn about Novotech's growth in the Republic of Korea and the central role their business plays in bringing Korean biotech innovation to the world. Investment NSW looks forward to continuing to support Novotech as it generates export dollars for our state while helping people around the world tackle serious health issues.' Minister Chanthivong was joined by a delegation including: Brooke O'Rourke, Chief of Staff to Minister Chanthivong. Rebecca McPhee, Deputy Secretary of Investment NSW. David Lawson, NSW Trade & Investment Commissioner for Japan & Korea. Yoojin Kim, NSW Trade & Investment Director for Korea. The delegation engaged with Novotech leaders Dr. Yooni Kim, Hyun Kim, and Lilian Kim, who shared insights into Novotech's growth as a global clinical research organization and the expanding role of South Korea as a premier destination for clinical trials. 'We are honored that the Australian NSW Trade Minister and senior officials from NSW Investment have selected Novotech as a leading example of collaboration between Australia and South Korea,' said Dr. Yooni Kim, Managing Director – Asia-Pacific at Novotech. 'This visit reinforces the strong and growing partnership between the two countries in the clinical research and biopharmaceutical sector. As the largest Australian-founded global services company operating in South Korea, Novotech is committed to creating more success stories that demonstrate the value of this collaboration. I believe Novotech's strong partnership with the Australian NSW government and their NSW Investment can mutually benefit Korean biotech companies and the Australian clinical trial market.' The discussion reinforced Novotech's strong partnership with Australia, supported by a track record of successful clinical trials and a shared vision for future innovation. With increasing interest from Korean biotechs to conduct research in Australia, both parties explored opportunities to enhance bilateral cooperation and accelerate cross-border clinical development. Novotech, recently recognized as the Best CRO in Australia by IMAPAC's Asia-Pacific Biopharma Excellence Awards, continues to solidify its position as the region's leading clinical development partner. The company offers Korean biotech sponsors seamless access to Australia's world-class research infrastructure, regulatory expertise, and accelerated clinical pathways. Through its integrated full-service model, Novotech enables Korean biotechs to confidently expand early-phase programs into Australia, backed by deep regional knowledge and globally aligned operational standards. About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results For more information or to speak to an expert team member visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Business Wire
5 days ago
- Business
- Business Wire
New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration
SYDNEY--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister's visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. Novotech, a leading global CRO trusted by biotech and mid-sized pharma to guide drug development, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. Share 'Novotech is a fantastic success story demonstrating the global value of NSW's strengths in life sciences and clinical trials,' said Minister Chanthivong. 'I was thrilled to learn about Novotech's growth in the Republic of Korea and the central role their business plays in bringing Korean biotech innovation to the world. Investment NSW looks forward to continuing to support Novotech as it generates export dollars for our state while helping people around the world tackle serious health issues.' Minister Chanthivong was joined by a delegation including: Brooke O'Rourke, Chief of Staff to Minister Chanthivong. Rebecca McPhee, Deputy Secretary of Investment NSW. David Lawson, NSW Trade & Investment Commissioner for Japan & Korea. Yoojin Kim, NSW Trade & Investment Director for Korea. The delegation engaged with Novotech leaders Dr. Yooni Kim, Hyun Kim, and Lilian Kim, who shared insights into Novotech's growth as a global clinical research organization and the expanding role of South Korea as a premier destination for clinical trials. 'We are honored that the Australian NSW Trade Minister and senior officials from NSW Investment have selected Novotech as a leading example of collaboration between Australia and South Korea,' said Dr. Yooni Kim, Managing Director – Asia-Pacific at Novotech. 'This visit reinforces the strong and growing partnership between the two countries in the clinical research and biopharmaceutical sector. As the largest Australian-founded global services company operating in South Korea, Novotech is committed to creating more success stories that demonstrate the value of this collaboration. I believe Novotech's strong partnership with the Australian NSW government and their NSW Investment can mutually benefit Korean biotech companies and the Australian clinical trial market.' The discussion reinforced Novotech's strong partnership with Australia, supported by a track record of successful clinical trials and a shared vision for future innovation. With increasing interest from Korean biotechs to conduct research in Australia, both parties explored opportunities to enhance bilateral cooperation and accelerate cross-border clinical development. Novotech, recently recognized as the Best CRO in Australia by IMAPAC's Asia-Pacific Biopharma Excellence Awards, continues to solidify its position as the region's leading clinical development partner. The company offers Korean biotech sponsors seamless access to Australia's world-class research infrastructure, regulatory expertise, and accelerated clinical pathways. Through its integrated full-service model, Novotech enables Korean biotechs to confidently expand early-phase programs into Australia, backed by deep regional knowledge and globally aligned operational standards. About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results
Korea Herald
23-05-2025
- Business
- Korea Herald
LS consults with Vietnam for rare earth development
LS Eco Energy, a Vietnam-based cable manufacturer under Korea's LS Cable & System, said Friday that its top executives met with the Vietnamese deputy industry minister to discuss ways to cooperate in developing the country's rare earth supply chain. LS Cable & System CEO Koo Bon-kyu and LS Eco Energy CEO Lee Sang-ho had a meeting with Deputy Minister of Industry and Trade Nguyen Hoang Long on Thursday to request regulatory support. The talks focused particularly on approvals related to radioactive materials and environmental standards, as well as cooperation with local mining companies, according to the firm. LS Eco Energy aims to build a rare earth value chain in Vietnam, from mining to metal production. The company plans to leverage Vietnam's rich reserves of materials, which are essential for technologies such as robotics and electric vehicle motors. At the meeting, the deputy minister expressed openness to providing government-level support for the rare earth supply chain and showed optimism about the collaboration model's potential to enhance Vietnam's industrial capabilities, LS said. While believed to hold about 18 percent of global rare earth reserves, second to China, the country allows only a few approved companies to produce the minerals under strict regulations. LS Eco Energy partnered with local refiner Hung Thinh Minerals to secure rare earth materials from 2025, but local challenges, including delays in processing facility construction, have postponed the project. 'With three decades of business experience in Vietnam, we are confident we can be the ideal partner to help position the country as a global hub for the rare earth industry,' said CEO Lee.
Roya News
20-05-2025
- Politics
- Roya News
Safadi visits Syria as Jordan, Damascus agree on cooperation roadmap
Jordan's Deputy Prime Minister and Minister of Foreign Affairs, Ayman Safadi, arrived in Damascus on Teusday, leading a high-level delegation on a working visit aimed at restoring and strengthening ties between Jordan and Syria. The visit marks a new phase in bilateral relations after years of tension and regional instability. According to Jordan's state media, Safadi and Syrian officials agreed on a roadmap for cooperation across key sectors, including water, energy, transport, trade, and health. The Jordanian delegation included Minister of Water and Irrigation Raed Abu Al-Saud, Minister of Industry and Trade Yarub Qudah, Minister of Energy Saleh Kharabsheh, and Minister of Transport Wesam Tahtamouni. During a joint press conference with Syrian Foreign Minister Asaad Hassan al-Shaibani, Safadi said the roadmap reflects Jordan's commitment, under the direction of King Abdullah II, to strengthen regional cooperation and support Syria's recovery. 'We agreed today on a practical roadmap covering multiple sectors. Our next step is implementation,' he said. Establishing higher coordination council Al-Shaibani announced the signing of an agreement to establish a Higher Coordination Council between the two countries, covering all ministries and designed to move joint projects toward implementation. He described the visit as 'a historic turning point,' and praised Jordan's role, saying, 'Jordan has been more eager than us to push this process forward.' Addressing shared challenges Safadi emphasized the importance of tackling shared challenges, particularly drug and arms smuggling across the Syrian-Jordanian border — a long-standing concern for Amman. He also condemned ongoing Israeli strikes on Syrian territory, calling them 'unjustified, immoral violations' that threaten both countries' security. Jordan backs Syria's recovery Safadi reaffirmed Jordan's full support for Syria during its transitional phase. 'A successful Syrian recovery is a success for Jordan and the region,' he said. He called for lifting sanctions on Syria, arguing they hinder reconstruction and development. Lifting them, he added, would enable Syrian authorities to rebuild and invite international and private sector engagement. On Syrian refugees in Jordan Safadi noted that Jordan hosts over 1.3 million Syrian refugees, with only 10% living in camps. He stressed that their voluntary return depends on the success of Syria's recovery. 'Jordan will continue to support Syria until it has the tools needed to rebuild,' he said.
